Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys

被引:63
作者
Kageyama, S
Yamamoto, H
Nakazawa, H
Matsushita, J
Kouyama, T
Gonsho, A
Ikeda, Y
Yoshimoto, R
机构
[1] Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan
[2] Ajinomoto Co Inc, Pharmaceut Res Labs, Kanagawa, Japan
[3] Ajinomoto Co Inc, Dev Res Labs, Kanagawa, Japan
关键词
von Willebrand factor; platelets; shear stress; bleeding time; AJW200;
D O I
10.1161/hq0102.101520
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The interaction between platelet glycoprotein Ib and von Willebrand factor (vWF) plays a crucial role in platelet-mediated thrombus formation under high-shear-stress conditions. The aim of this study was to investigate the antiplatelet profile of a humanized anti-vWF monoclonal antibody, AJW200. In vitro studies were performed with a modified cone-and-plate viscometer and human platelets. AJW200 inhibited high-shear-stress-induced platelet adhesion, aggregation, and thrombin generation, but it did not have such effects under low-shear-stress conditions. Although abciximab inhibited platelet aggregation under both shear stress conditions, it did not inhibit platelet adhesion and thrombin generation. In addition, the pharmacokinetics and pharmacodynamics of AJW200 were evaluated in cynomolgus monkeys. Sustained inhibition of ristocetin-induced platelet aggregation was observed over 24 hours, 6 days, and 2 weeks after a single bolus injection of 0.3, 1, and 3 mg/kg, respectively. Moderate prolongation of the bleeding time was observed at the doses of 1 and 3 mg/kg. Abciximab markedly prolonged the bleeding time at 0.4 mg/kg, at which concentration complete inhibition of ADP-induced platelet aggregation was observed. These results suggest that glycoprotein Ib-vWF blockade with AJW200 results in a sustained antiplatelet effect without extensive prolongation of the bleeding time, probably due to a shear-stress-dependent inhibitory action.
引用
收藏
页码:187 / 192
页数:6
相关论文
共 17 条
[1]   LACK OF USEFULNESS OF PROLONGED BLEEDING TIMES IN PREDICTING HEMORRHAGIC EVENTS IN PATIENTS RECEIVING THE 7E3 GLYCOPROTEIN IIB/IIIA PLATELET ANTIBODY [J].
BERNARDI, MM ;
CALIFF, RM ;
KLEIMAN, N ;
ELLIS, SG ;
TOPOL, EJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (15) :1121-1125
[2]  
DALESSIO P, 1990, THROMB HAEMOSTASIS, V64, P227
[3]   AJvW-2, an anti-vWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes [J].
Eto, K ;
Isshiki, T ;
Yamamoto, H ;
Takeshita, S ;
Ochiai, M ;
Yokoyama, N ;
Yoshimoto, R ;
Ikeda, Y ;
Sato, T .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (04) :877-882
[4]   Enhanced shear-induced platelet aggregation in acute myocardial infarction [J].
Goto, S ;
Sakai, H ;
Goto, M ;
Ono, M ;
Ikeda, Y ;
Handa, S ;
Ruggeri, ZM .
CIRCULATION, 1999, 99 (05) :608-613
[5]   THE ROLE OF VONWILLEBRAND-FACTOR AND FIBRINOGEN IN PLATELET-AGGREGATION UNDER VARYING SHEAR-STRESS [J].
IKEDA, Y ;
HANDA, M ;
KAWANO, K ;
KAMATA, T ;
MURATA, M ;
ARAKI, Y ;
ANBO, H ;
KAWAI, Y ;
WATANABE, K ;
ITAGAKI, I ;
SAKAI, K ;
RUGGERI, ZM .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (04) :1234-1240
[6]   Anti-human von willebrand factor monoclonal antibody AJvW3 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs [J].
Kageyama, S ;
Yamamoto, H ;
Yoshimoto, R .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (10) :2303-2308
[7]   Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor [J].
Kageyama, S ;
Yamamoto, H ;
Nagano, M ;
Arisaka, H ;
Kayahara, T ;
Yoshimoto, R .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (01) :165-171
[8]   Anti-human vWF monoclonal antibody, AJvW-2 fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs [J].
Kageyama, S ;
Yamamoto, H ;
Nakazawa, H ;
Yoshimoto, R .
THROMBOSIS RESEARCH, 2001, 101 (05) :395-404
[9]   ABOLITION OF CYCLIC FLOW VARIATIONS IN STENOSED, ENDOTHELIUM-INJURED CORONARY-ARTERIES IN NONHUMAN-PRIMATES WITH A PEPTIDE FRAGMENT (VCL) DERIVED FROM HUMAN PLASMA VON-WILLEBRAND-FACTOR GLYCOPROTEIN-IB BINDING DOMAIN [J].
MCGHIE, AI ;
MCNATT, J ;
EZOV, N ;
CUI, KX ;
MOWER, LK ;
HAGAY, Y ;
BUJA, LM ;
GARFINKEL, LI ;
GORECKI, M ;
WILLERSON, JT .
CIRCULATION, 1994, 90 (06) :2976-2981
[10]   Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody - Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and ''clinical restenosis'' [J].
Reverter, JC ;
Beguin, S ;
Kessels, H ;
Kumar, R ;
Hemker, HC ;
Coller, BS .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (03) :863-874